Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
REM-422 by Remix Therapeutics for Adenoid Cystic Carcinoma (ACC): Likelihood of Approval
REM-422 is under clinical development by Remix Therapeutics and currently in Phase I for Adenoid Cystic Carcinoma (ACC). According to...
REM-422 by Remix Therapeutics for Myelodysplastic Syndrome: Likelihood of Approval
REM-422 is under clinical development by Remix Therapeutics and currently in Phase I for Myelodysplastic Syndrome. According to GlobalData, Phase...
REM-422 by Remix Therapeutics for Refractory Acute Myeloid Leukemia: Likelihood of Approval
REM-422 is under clinical development by Remix Therapeutics and currently in Phase I for Refractory Acute Myeloid Leukemia. According to...
REM-422 by Remix Therapeutics for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
REM-422 is under clinical development by Remix Therapeutics and currently in Phase I for Relapsed Acute Myeloid Leukemia. According to...